Lu-177 decays by beta emission and gamma emission with a half-life of 6.65 days. It is typically produced in nuclear reactors by neutron irradiation of lutetium-176. The resulting Lu-177 is then chemically separated and incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of nuclear reactors, lutetium-176 targets, and radiochemistry facilities. Logistical challenges include the transport and handling of radioactive materials. Accessibility for developing countries is influenced by the specialised facilities and regulatory requirements.
Overview
Maturity
Lu-177 production and application are well-established, with increasing use in targeted radionuclide therapy.
Safety considerations
Lu-177 is a radioactive isotope that emits beta and gamma radiation, requiring careful handling procedures and physical shielding to minimise radiation exposure.
Security considerations
All radioactive isotopes can be misused, and as such, robust security protocols around chain of custody, inventory management, and physical security are critical.
Safeguarding considerations
Due to the absence of nuclear materials, IAEA safeguards are not applicable.
